AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial

AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial

Bibliographic Details
Main Authors: DiNardo, CD, de Botton, S, Risueño, A, Schuh, AC, Löwenberg, B, Kim, HJ, Vyas, P, Wei, AH, Stein, EM, Döhner, H, Fathi, AT, Martin-Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Format: Conference item
Language:English
Published: Elsevier 2022

Similar Items

Similar Items